$CRVO
CervoMed Inc.

2024 Q4 Form 10-Q Financial Statement

#000143774924034344 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $1.940M
YoY Change 27.07%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.211M
YoY Change -8.26%
% of Gross Profit
Research & Development $5.125M
YoY Change 186.08%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $7.336M
YoY Change 74.6%
Operating Profit -$5.396M
YoY Change 101.72%
Interest Expense $646.2K
YoY Change 1192.34%
% of Operating Profit
Other Income/Expense, Net $642.7K
YoY Change -86.68%
Pretax Income -$4.754M
YoY Change -321.09%
Income Tax
% Of Pretax Income
Net Earnings -$4.754M
YoY Change -321.06%
Net Earnings / Revenue -245.06%
Basic Earnings Per Share -$0.55
Diluted Earnings Per Share -$0.55
COMMON SHARES
Basic Shares Outstanding 8.254M 8.254M
Diluted Shares Outstanding 8.703M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.66M
YoY Change 347.76%
Cash & Equivalents $7.744M
Short-Term Investments $38.91M
Other Short-Term Assets $74.34K
YoY Change -48.24%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $48.81M
YoY Change 312.13%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $73.94K
YoY Change -61.97%
Total Long-Term Assets $73.94K
YoY Change -61.97%
TOTAL ASSETS
Total Short-Term Assets $48.81M
Total Long-Term Assets $73.94K
Total Assets $48.88M
YoY Change 306.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.082M
YoY Change 102.78%
Accrued Expenses $2.164M
YoY Change 56.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.246M
YoY Change 31.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.246M
Total Long-Term Liabilities $0.00
Total Liabilities $3.246M
YoY Change 31.77%
SHAREHOLDERS EQUITY
Retained Earnings -$64.00M
YoY Change 22.84%
Common Stock $8.253K
YoY Change 45.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $45.64M
YoY Change
Total Liabilities & Shareholders Equity $48.88M
YoY Change 306.08%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$4.754M
YoY Change -321.06%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.855M
YoY Change -279.8%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.602M
YoY Change
Cash From Investing Activities $2.602M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -13.34K
YoY Change -100.12%
NET CHANGE
Cash From Operating Activities -4.855M
Cash From Investing Activities 2.602M
Cash From Financing Activities -13.34K
Net Change In Cash -2.266M
YoY Change -116.25%
FREE CASH FLOW
Cash From Operating Activities -$4.855M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5674520
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5125097 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2210927 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0645032
dei Entity Address Address Line1
EntityAddressAddressLine1
20 Park Plaza, Suite 424
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
744-4400
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7743667 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
38913236 usd
dei Document Type
DocumentType
10-Q
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37942
dei Entity Registrant Name
EntityRegistrantName
CervoMed Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7792846 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4753541 usd
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8253741
CY2024Q3 crvo Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
1888879 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2163936 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2595747 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1082435 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1933276 usd
us-gaap Operating Expenses
OperatingExpenses
9986739 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2675129 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10986310 usd
dei Trading Symbol
TradingSymbol
CRVO
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
73937 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7770 usd
CY2024Q3 us-gaap Assets
Assets
48883867 usd
CY2023Q4 us-gaap Assets
Assets
9972521 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
662471 usd
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5674520
us-gaap Revenues
Revenues
4654294 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11711746 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5583149 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6850536 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4403590 usd
us-gaap Operating Expenses
OperatingExpenses
18562282 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5332445 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5422192 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1405246 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
100778 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1401529 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5522970 usd
us-gaap Net Income Loss
NetIncomeLoss
-9584781 usd
us-gaap Net Income Loss
NetIncomeLoss
190525 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001053691
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q3 crvo Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0 usd
crvo Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0 usd
CY2024Q3 crvo Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0 usd
crvo Impairment Of Marketable Securities
ImpairmentOfMarketableSecurities
0 usd
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q4 crvo Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
1256501 usd
CY2024Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
264148 usd
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
915404 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
48809930 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9964751 usd
CY2024Q3 us-gaap Liabilities
Liabilities
3246371 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8253741
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8253741
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
8253 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5674 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
109531651 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61811889 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
123162 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64025570 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54440789 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
45637496 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7376774 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48883867 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9972521 usd
CY2024Q3 us-gaap Revenues
Revenues
1939751 usd
CY2023Q3 us-gaap Revenues
Revenues
1526482 usd
us-gaap Revenues
Revenues
7575972 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1791487 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2410124 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
7336024 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4201611 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5396273 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3440 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4777824 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3717 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
646172 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
47667 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
642732 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4825491 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2150362 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8702764
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3308302
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7861757
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1458415
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.37
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8702764
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3766700
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7861757
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2209407
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
142864 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
123162 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4610677 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2150362 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9461619 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
190525 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
49976958 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
271215 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
142864 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4753541 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
45637496 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7376774 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46398606 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
255724 usd
crvo Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
0 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1068011 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
123162 usd
us-gaap Net Income Loss
NetIncomeLoss
-9584781 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
45637496 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-35111404 usd
CY2023Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
24287211 usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
6989749 usd
CY2023Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
10339114 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
810000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
109168 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2150362 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
9574200 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-33285059 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
24287211 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
6989749 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
10339114 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
810000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
242660 usd
us-gaap Net Income Loss
NetIncomeLoss
190525 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
9574200 usd
us-gaap Net Income Loss
NetIncomeLoss
-9584781 usd
us-gaap Net Income Loss
NetIncomeLoss
190525 usd
crvo Accretion Expense Net
AccretionExpenseNet
-822198 usd
crvo Accretion Expense Net
AccretionExpenseNet
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1068011 usd
us-gaap Share Based Compensation
ShareBasedCompensation
242660 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-0 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
5424251 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
698545 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1549061 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
419964 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
382675 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
486384 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
699008 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-651256 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
547051 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8479909 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4911393 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
44467876 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
-0 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6500000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37967876 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
crvo Proceeds From Net Assets Assumed In Connection With Reverse Recapitalization
ProceedsFromNetAssetsAssumedInConnectionWithReverseRecapitalization
11887757 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
46398606 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
810000 usd
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1455268 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46398606 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11242489 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-49179 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6331096 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7792846 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4093579 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7743667 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10424675 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
24287211 usd
crvo Merger Costs In Accounts Payable And Accrued Expenses
MergerCostsInAccountsPayableAndAccruedExpenses
0 usd
crvo Merger Costs In Accounts Payable And Accrued Expenses
MergerCostsInAccountsPayableAndAccruedExpenses
93375 usd
us-gaap Stock Issued1
StockIssued1
255724 usd
us-gaap Stock Issued1
StockIssued1
0 usd
crvo Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
496 usd
crvo Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>1. The Company and Description of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is a corporation organized under the laws of the state of Delaware and headquartered in Boston, Massachusetts. The Company is a clinical-stage biotechnology company developing treatments for age-related neurologic disorders. The Company is currently focused on developing of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38α. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders, and is currently being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b study in patients with Early-Stage DLB, funded by a $21.3 million grant from the NIA.</p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of unaudited condensed consolidated interim financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, grant revenue, expenses, and related disclosures. On an ongoing basis, the Company’s management evaluates its estimates, including estimates related to money market accounts, clinical trial accruals, stock-based compensation expense, grant revenue, and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ significantly from those estimates or assumptions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in a financial institution in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at a financial institution that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. Management also believes that the Company is not exposed to significant credit risk as it relates to marketable securities because the Company invests in U.S. government securities and commercial paper.</p>
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4753541 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2150362 usd
us-gaap Net Income Loss
NetIncomeLoss
-9584781 usd
us-gaap Net Income Loss
NetIncomeLoss
190525 usd
CY2024Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
-0 usd
CY2023Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
4778251 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
-0 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
5424251 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4753541 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2627889 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9584781 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5233726 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8702764
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3308302
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7861757
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1458415
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
458398
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
750992
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8702764
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3766700
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7861757
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2209407
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.37
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3167027
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
927797
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38790074 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
123684 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
522 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
38913236 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
12414000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-646000 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
11768000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-4778251 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
-6989749 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 usd
CY2024Q3 crvo Prepaid Clinical Expenses
PrepaidClinicalExpenses
1119402 usd
CY2023Q4 crvo Prepaid Clinical Expenses
PrepaidClinicalExpenses
711362 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
604543 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
436859 usd
CY2024Q3 crvo Prepaid Professional Services
PrepaidProfessionalServices
54361 usd
CY2023Q4 crvo Prepaid Professional Services
PrepaidProfessionalServices
37917 usd
CY2024Q3 crvo Prepaid Dues And Memberships Current
PrepaidDuesAndMembershipsCurrent
36230 usd
CY2023Q4 crvo Prepaid Dues And Memberships Current
PrepaidDuesAndMembershipsCurrent
0 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
74343 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
70363 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1888879 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1256501 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
739805 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1026054 usd
CY2024Q3 crvo Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
845063 usd
CY2023Q4 crvo Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
389045 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
449940 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
309062 usd
CY2024Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
30456 usd
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
120456 usd
CY2024Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
98672 usd
CY2023Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
88659 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2163936 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1933276 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
26292 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
23000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
8400 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
8000 usd
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.90 pure
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04 pure
CY2024Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
49135 usd
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
136739 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3082891
CY2024Q1 crvo Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
499995
CY2024Q1 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
36
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
495959
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
63422
CY2023Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
12.78
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
800000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
271215 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
109168 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1068011 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
242660 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
349374
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
51.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
207284
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
23499
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
382.72
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
533159
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
270707
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
32.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd

Files In Submission

Name View Source Status
0001437749-24-034344-index-headers.html Edgar Link pending
0001437749-24-034344-index.html Edgar Link pending
0001437749-24-034344.txt Edgar Link pending
0001437749-24-034344-xbrl.zip Edgar Link pending
crvo-20240930.xsd Edgar Link pending
crvo20240930_10q.htm Edgar Link pending
crvo20240930_10qimg001.jpg Edgar Link pending
ex_744569.htm Edgar Link pending
ex_744570.htm Edgar Link pending
ex_744571.htm Edgar Link pending
ex_744572.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
crvo-20240930_pre.xml Edgar Link unprocessable
crvo-20240930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crvo20240930_10q_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
crvo-20240930_def.xml Edgar Link unprocessable
crvo-20240930_lab.xml Edgar Link unprocessable